ArticleFrontiers in immunology2022
SFRP4
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Ultrasound-Assisted Cerium-Doped Zeolite Nanocomplex Attenuates Adenomyosis via Wnt/beta-Catenin Pathway Inhibition and IGFBP5 Downregulation in SFRP4+ NKT Cells.Physiological research · 2026Article
- Decoding apoptosis, ferroptosis, and inflammatory cell death in adenomyosis at single-cell resolution.Briefings in bioinformatics · 2026Article
- The interaction between inflammation and estrogen in adenomyosis : from molecular mechanisms to therapeutic strategies.Seminars in immunopathology · 2026Review
- CD11dGenes and immunity · 2026Article
- Decoding adenomyosis pathogenesis using an assembloid model.Science China. Life sciences · 2026Article
- Inflammatory and Molecular Mechanisms of Adenomyosis Associated Pain: Insights from Multiple Analytic Approaches.Journal of pain research · 2026Article
- Nociceptive Nerve-Derived CGRP Exacerbates Uterine Fibrogenesis in Adenomyosis by Promoting CD140bAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Single-Cell Analysis Reveals Fibroblast-Derived Migrasomes as CXCL12 Carriers Promoting Skin Wound Repair.Journal of extracellular vesicles · 2025Article
- Integrated multi-omics analysis and experimental verification reveal the involvement of the PI3K/Akt signaling pathway in myometrial fibrosis of adenomyosis.Scientific reports · 2025Article
- Review
- Comprehensive transcriptional atlas of human adenomyosis deciphered by the integration of single-cell RNA-sequencing and spatial transcriptomics.Protein & cell · 2024Article
- Killer Cell Immunoglobulin-like Receptor Genotypes and Reproductive Outcomes in a Group of Infertile Women: A Romanian Study.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adenomyosis is an estrogen-dependent gynecological disease. The pathogenesis of chronic pain, the main clinical symptom of adenomyosis, remains undefined. As a combination lymphocyte with both T-cell and natural killer (NK)-cell properties, NK T (NKT) cells play a role in immune defense against numerous diseases and modulate cell differentiation. Method: This study analyzed the tissue-cell samples from adenomyosis with or without pain by single-cell sequencing. Result: We found a specific population of secreted frizzled-related protein 4 (SFRP4) Conclusion: Collectively, these findings suggest that SFRP4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.